CMCharles Morgat

Charles Morgat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Morgat has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraoperative Visualization of a Thebesian Vein Influencing Atrial Helix-Fixation Leadless Pacemaker Implantation Strategy

    by Charles Morgat, Claude Mariottini, Yann Diascorn, Sok-Sithikun Bun, Hugo Marchand

  • Open Access

    Software-based analysis of T-wave morphology: identifying the electrocardiogram signature of high-risk long QT syndrome

    by Alessandra Pia Porretta, Charles Morgat, Elodie Surget, Véronique Fressart, Adrien Bloch, Nathalie Neyroud, Fabio Badilini, Martino Vaglio, Isabelle Denjoy, Fabrice Extramiana

    Aims: Despite T-wave morphology abnormalities being well-known distinctive ECG features in patients with long QT syndrome (LQTS), the subjectivity of qualitative ‘eyeballing’ in T-wave characterization still hampers its integration into diagnostic/prognostic criteria. We herein evaluated whether our quantitative software-based analysis of T-wave morphology (AnTwM) applied to digital ECGs may identify predictors of cardiac events (CEs) in our cohort of LQTS patients. Methods and results: We enrolled LQT1, LQT2, and LQT3 patients having at least one digital ECG from our cohort of genotype-confirmed LQTS patients. Automated AnTwM analysis, using Glasgow and Bravo algorithms embedded in the CalECG software (AMPS-IIc, USA), provided scalar descriptors of ventricular repolarization. Cox regression analyses identified potential predictors of CEs (i.e. syncope, sudden cardiac death, resuscitated cardiac arrest, or appropriate shock delivered by implantable cardioverter defibrillators). A total of 467 (58% female) patients were followed up for 15 ± 9 years, including 253 (54.2%) LQT1, 182 (39%) LQT2, and 32 (6.8%) LQT3 patients. Corrected QT interval predicted CEs in the whole population (1 ms QTc increase: HR = 1.01, 95% CI: 1.0–1.01, P = 0.03) but not across genotyped subpopulations. Genotype-specific ECG markers associated with a greater risk of CEs were (i) those expressing a delayed accumulation of the mid-late T-wave area (decreased t25 and increased t50) among LQT1 patients and (ii) those expressing T-wave flattening/widening (decreased T-wave ascending/descending slopes) among LQT2 patients. Conclusion: The software-based AnTwM on digital ECGs represented a reliable tool in clinical practice and identified unique ECG T-wave ‘fingerprints’ that allowed prediction of CEs in a genotype-specific manner.


  • Open Access

    Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

    by Charles Morgat, VérOnique Fressart, Alessandra Pia Porretta, Nathalie Neyroud, Anne Messali, Yassine Temmar, Vincent Algalarrondo, Elodie Surget, Adrien Bloch, Antoine Leenhardt, et al.

    KCNQ1 mutations cause QTc prolongation increasing life-threatening arrhythmias risks. Heterozygous mutations [type 1 long QT syndrome (LQT1)] are common. Homozygous KCNQ1 mutations cause type 1 Jervell and Lange–Nielsen syndrome (JLNS) with deafness and higher sudden cardiac death risk. KCNQ1 variants causing JLNS or LQT1 might have distinct phenotypic expressions in heterozygous patients. The aim of this study is to evaluate QTc duration and incidence of long QT syndrome–related cardiac events according to genetic presentation. We enrolled LQT1 or JLNS patients with class IV/V KCNQ1 variants from our inherited arrhythmia clinic (September 1993 to January 2023). Medical history, ECG, and follow-up were collected. Additionally, we conducted a thorough literature review for JLNS variants. Survival curves were compared between groups, and multivariate Cox regression models identified genetic and clinical risk factors. Among the 789 KCNQ1 variant carriers, 3 groups were identified: 30 JLNS, 161 heterozygous carriers of JLNS variants (HTZ-JLNS), and 550 LQT1 heterozygous carriers of non-JLNS variants (HTZ-Non-JLNS). At diagnosis, mean age was 3.4 ± 4.7 years for JLNS, 26.7 ± 21 years for HTZ-JLNS, and 26 ± 21 years for HTZ-non-JLNS; 55.3% were female; and the mean QTc was 551 ± 54 ms for JLNS, 441 ± 32 ms for HTZ-JLNS, and 467 ± 36 ms for HTZ-Non-JLNS. Patients with heterozygous JLNS mutations (HTZ-JLNS) represented 22% of heterozygous KCNQ1 variant carriers and had a lower risk of cardiac events than heterozygous non-JLNS variant carriers (HTZ-Non-JLNS) [hazard ratio (HR) = 0.34 (0.22–0.54); P < 0.01]. After multivariate analysis, four genetic parameters were independently associated with events: haploinsufficiency [HR = 0.60 (0.37–0.97); P = 0.04], pore localization [HR = 1.61 (1.14–1.2.26); P < 0.01], C-terminal localization [HR = 0.67 (0.46–0.98); P = 0.04], and group [HR = 0.43 (0.27–0.69); P < 0.01]. Heterozygous carriers of JLNS variants have a lower risk of cardiac arrhythmic events than other LQT1 patients.